

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number  
WO 02/088711 A2

- (51) International Patent Classification<sup>7</sup>: G01N 33/48
- (21) International Application Number: PCT/CA02/00627
- (22) International Filing Date: 29 April 2002 (29.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/846,344 30 April 2001 (30.04.2001) US
- (71) Applicant: SYN.X PHARMA, INC. [CA/CA]; 6354 Viscount Road, Mississauga, Ontario L4V 1H3 (CA).
- (72) Inventors: JACKOWSKI, George; 11725 Keele Street R1, Kettleby, Ontario L0G 1J0 (CA). THATCHER, Brad; 12 Beaverdale Road, Toronto, Ontario M8Y 3Y4 (CA). VREES, Tammy; 215 Bronte Road, Oakville, Ontario L6L 3C5 (CA). YANTHA, Jason; 44 St. Joseph Street, Apartment 2102, Toronto, Ontario M4Y 2W4 (CA). MARSHALL, John; 95 Parkside Drive, Toronto, Ontario M6R 2V3 (CA).
- (74) Agent: SINGLEHURST, John, C.; Finlayson & Singlehurst, 70 Gloucester Street, Ottawa, Ontario K2P 0A2 (CA).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:  
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations

[Continued on next page]

(54) Title: BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 2021 DALTONS

Biopolymer Indicative of Disease State - BW 2021

Code #	Gender	Age	Patient History	Disease	Year	Protein Name	Sequence
BJ CON 01	M	53		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 02	F	77		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 03	M	80		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4202	M	81		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4209	M	78		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4214	M	83		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4229	M	83		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
164-358	M	73		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
754-489	M	83		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 09	M	85		Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 10	F	60		ME	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 11	F	85		ME	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 12	M	86		ME	2021	Completion CDF	CSSGTHRWWEASALLRG
BJ CON 13	M	85		ME	2021	Completion CDF	CSSGTHRWWEASALLRG
1H5-3-223	M	87		ME	2021	Completion CDF	CSSGTHRWWEASALLRG
1H5-3-228	M	87		ME	2021	Completion CDF	CSSGTHRWWEASALLRG
1H5-3-233	M	81	STAGE 3	ME	2021	Completion CDF	CSSGTHRWWEASALLRG
23797 - KL	F	86	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23793 - MMB	F	87	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
10209 - HMI	F	72	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
22103 - GM	F	77	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
11113 - GR	F	69	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23004 - GFB	F	87	STAGE 3 - DEAD	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23402 - PM	M	87	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
10204 - HFB	M	78	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
22803 - HG	M	80	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23816 - JOK	M	43	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
10883 - GY	M	81	Acute MI - STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
33471 - FB	M	69	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23813 - CL	F	88	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23130 - LR	M	81	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23105 - FC	M	84	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23116 - FC	M	88	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
20414 - TYO	F	78	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23130 - ER	M	81	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
23134 - JC	M	85	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
20107 - LGB	M	76	STAGE 3	CHF	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4202				Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4209				Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4214				Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
YH4229				Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
164-358				Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG
754-489				Type 2 Diabetes	2021	Completion CDF	CSSGTHRWWEASALLRG

(57) Abstract: The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

WO 02/088711 A2

WO 02/088711 A2



**Published:**

— without international search report and to be republished  
upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 2021 DALTONS

### FIELD OF THE INVENTION

This invention relates to the field of characterizing the existence of a disease state; particularly to the utilization of mass spectroscopy to elucidate particular biopolymer markers indicative of disease state, and most particularly to specific  
5 biopolymer sequences having a unique relationship to at least one particular disease state.

### BACKGROUND OF THE INVENTION

Methods utilizing mass spectrometry for the analysis of a target polypeptide have been taught wherein the polypeptide is first solubilized in an appropriate solution  
10 or reagent system. The type of solution or reagent system, e.g., comprising an organic or inorganic solvent, will depend on the properties of the polypeptide and the type of mass spectrometry performed and are well known in the art (see, e.g., Vorm et al. (1994) Anal. Chem. 66:3281 (for MALDI) and Valaskovic et al. (1995) Anal. Chem. 67:3802 (for ESI). Mass spectrometry of peptides is further disclosed, e.g., in WO  
15 93/24834 by Chait et al.

In one prior art embodiment, the solvent is chosen so that the risk that the molecules may be decomposed by the energy introduced for the vaporization process is considerably reduced, or even fully excluded. This can be achieved by embedding the sample in a matrix, which can be an organic compound, e.g., sugar, in particular  
20 pentose or hexose, but also polysaccharides such as cellulose. These compounds are decomposed thermolytically into CO<sub>2</sub> and H<sub>2</sub>O so that no residues are formed which might lead to chemical reactions. The matrix can also be an inorganic compound, e.g., nitrate of ammonium which is decomposed practically without leaving any residues. Use of these and other solvents are further disclosed in U.S. Pat. No. 5,062,935 by  
25 Schlag et al.

Prior art mass spectrometer formats for use in analyzing the translation products include ionization (I) techniques, including but not limited to matrix assisted laser desorption (MALDI), continuous or pulsed electrospray (ESI) and related methods

(e.g., IONSpray or THERMOSpray), or massive cluster impact (MCI); these ion sources can be matched with detection formats including linear or non-linear reflection time-of-flight (TOF), single or multiple quadrupole, single or multiple magnetic sector, Fourier Transform ion cyclotron resonance (FTICR), ion trap, and combinations thereof

5 (e.g., ion-trap/time-of-flight). For ionization, numerous matrix/wavelength combinations (MALDI) or solvent combinations (ESI) can be employed. Subattomole levels of protein have been detected, for example, using ESI (Valaskovic, G. A. et al., (1996) *Science* 273:1199-1202) or MALDI (Li, L. et al., (1996) *J. Am. Chem. Soc.* 118:1662-1663) mass spectrometry.

10 ES mass spectrometry has been introduced by Fenn et al. (*J. Phys. Chem.* 88, 4451-59 (1984); PCT Application No. WO 90/14148) and current applications are summarized in recent review articles (R. D. Smith et al., *Anal. Chem.* 62, 882-89 (1990) and B. Ardrey, *Electrospray Mass Spectrometry, Spectroscopy Europe*, 4, 10-18 (1992)). MALDI-TOF mass spectrometry has been introduced by Hillenkamp et al.  
15 ("Matrix Assisted UV-Laser Desorption/Ionization: A New Approach to Mass Spectrometry of Large Biomolecules," *Biological Mass Spectrometry* (Burlingame and McCloskey, editors), Elsevier Science Publishers, Amsterdam, pp. 49-60, 1990). With ESI, the determination of molecular weights in femtomole amounts of sample is very accurate due to the presence of multiple ion peaks which all could be used for the mass  
20 calculation.

The mass of the target polypeptide determined by mass spectrometry is then compared to the mass of a reference polypeptide of known identity. In one embodiment, the target polypeptide is a polypeptide containing a number of repeated amino acids directly correlated to the number of trinucleotide repeats transcribed/translated from  
25 DNA; from its mass alone the number of repeated trinucleotide repeats in the original DNA which coded it, may be deduced.

U.S. Patent No. 6,020,208 utilizes a general category of probe elements (i.e., sample presenting means) with Surfaces Enhanced for Laser Desorption/Ionization (SELDI), within which there are three (3) separate subcategories. The SELDI process  
30 is directed toward a sample presenting means (i.e., probe element surface) with surface-associated (or surface-bound) molecules to promote the attachment (tethering or

anchoring) and subsequent detachment of tethered analyte molecules in a light-dependent manner, wherein the said surface molecule(s) are selected from the group consisting of photoactive (photolabile) molecules that participate in the binding (docking, tethering, or crosslinking) of the analyte molecules to the sample presenting means (by covalent attachment mechanisms or otherwise).

PCT/EP/04396 teaches a process for determining the status of an organism by peptide measurement. The reference teaches the measurement of peptides in a sample of the organism which contains both high and low molecular weight peptides and acts as an indicator of the organism's status. The reference concentrates on the measurement of low molecular weight peptides, i.e. below 30,000 Daltons, whose distribution serves as a representative cross-section of defined controls. Contrary to the methodology of the instant invention, the '396 patent strives to determine the status of a healthy organism, i.e. a "normal" and then use this as a reference to differentiate disease states. The present inventors do not attempt to develop a reference "normal", but rather strive to specify particular markers which are evidentiary of at least one specific disease state, whereby the presence of said marker serves as a positive indicator of disease. This leads to a simple method of analysis which can easily be performed by an untrained individual, since there is a positive correlation of data. On the contrary, the '396 patent requires a complicated analysis by a highly trained individual to determine disease state versus the perception of non-disease or normal physiology.

Richter et al, *Journal of Chromatography B*, 726(1999) 25-35, refer to a database established from human hemofiltrate comprised of a mass database and a sequence database. The goal of Richter et al was to analyze the composition of the peptide fraction in human blood. Using MALDI-TOF, over 20,000 molecular masses were detected representing an estimated 5,000 different peptides. The conclusion of the study was that the hemofiltrate (HF) represented the peptide composition of plasma. No correlation of peptides with relation to normal and/or disease states is made.

As used herein, "analyte" refers to any atom and/or molecule; including their complexes and fragment ions. In the case of biological molecules/macromolecules or "biopolymers", such analytes include but are not limited to: proteins, peptides, DNA, RNA, carbohydrates, steroids, and lipids. Note that most important biomolecules under

investigation for their involvement in the structure or regulation of life processes are quite large (typically several thousand times larger than H<sub>2</sub>O).

As used herein, the term "molecular ions" refers to molecules in the charged or ionized state, typically by the addition or loss of one or more protons (H<sup>+</sup>).

5           As used herein, the term "molecular fragmentation" or "fragment ions" refers to breakdown products of analyte molecules caused, for example, during laser-induced desorption (especially in the absence of added matrix).

As used herein, the term "solid phase" refers to the condition of being in the solid state, for example, on the probe element surface.

10           As used herein, "gas" or "vapor phase" refers to molecules in the gaseous state (i.e., in vacuo for mass spectrometry).

As used herein, the term "analyte desorption/ionization" refers to the transition of analytes from the solid phase to the gas phase as ions. Note that the successful desorption/ionization of large, intact molecular ions by laser desorption is relatively recent (circa 1988)--the big breakthrough was the chance discovery of an appropriate matrix (nicotinic acid).

15           As used herein, the term "gas phase molecular ions" refers to those ions that enter into the gas phase. Note that large molecular mass ions such as proteins (typical mass=60,000 to 70,000 times the mass of a single proton) are typically not volatile (i.e., they do not normally enter into the gas or vapor phase). However, in the procedure of the present invention, large molecular mass ions such as proteins do enter the gas or vapor phase.

20           As used herein in the case of MALDI, the term "matrix" refers to any one of several small, acidic, light absorbing chemicals (e.g., nicotinic or sinapinic acid) that is mixed in solution with the analyte in such a manner so that, upon drying on the probe element, the crystalline matrix-embedded analyte molecules are successfully desorbed (by laser irradiation) and ionized from the solid phase (crystals) into the gaseous or vapor phase and accelerated as intact molecular ions. For the MALDI process to be successful, analyte is mixed with a freshly prepared solution of the chemical matrix

25           (e.g., 10,000:1 matrix:analyte) and placed on the inert probe element surface to air dry

30           just before the mass spectrometric analysis. The large fold molar excess of matrix,

present at concentrations near saturation, facilitates crystal formation and entrapment of analyte.

As used herein, "energy absorbing molecules (EAM)" refers to any one of several small, light absorbing chemicals that, when presented on the surface of a probe, facilitate the neat desorption of molecules from the solid phase (i.e., surface) into the gaseous or vapor phase for subsequent acceleration as intact molecular ions. The term EAM is preferred, especially in reference to SELDI. Note that analyte desorption by the SELDI process is defined as a surface-dependent process (i.e., neat analyte is placed on a surface composed of bound EAM). In contrast, MALDI is presently thought to facilitate analyte desorption by a volcanic eruption-type process that "throws" the entire surface into the gas phase. Furthermore, note that some EAM when used as free chemicals to embed analyte molecules as described for the MALDI process will not work (i.e., they do not promote molecular desorption, thus they are not suitable matrix molecules).

As used herein, "probe element" or "sample presenting device" refers to an element having the following properties: it is inert (for example, typically stainless steel) and active (probe elements with surfaces enhanced to contain EAM and/or molecular capture devices).

As used herein, "MALDI" refers to Matrix-Assisted Laser Desorption/Ionization.

As used herein, "TOF" stands for Time-of-Flight.

As used herein, "MS" refers to Mass Spectrometry.

As used herein "MALDI-TOF MS" refers to Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

As used herein, "ESI" is an abbreviation for Electrospray ionization.

As used herein, "chemical bonds" is used simply as an attempt to distinguish a rational, deliberate, and knowledgeable manipulation of known classes of chemical interactions from the poorly defined kind of general adherence observed when one chemical substance (e.g., matrix) is placed on another substance (e.g., an inert probe element surface). Types of defined chemical bonds include electrostatic or ionic (+/-) bonds (e.g., between a positively and negatively charged groups on a protein surface),

covalent bonds (very strong or "permanent" bonds resulting from true electron sharing), coordinate covalent bonds (e.g., between electron donor groups in proteins and transition metal ions such as copper or iron), and hydrophobic interactions (such as between two noncharged groups).

---

5           As used herein, "electron donor groups" refers to the case of biochemistry, where atoms in biomolecules (e.g., N, S, O) "donate" or share electrons with electron poor groups (e.g., Cu ions and other transition metal ions).

          With the advent of mass spectroscopic methods such as MALDI and SELDI, researchers have begun to utilize a tool that holds the promise of uncovering countless  
10       biopolymers which result from translation, transcription and post-translational transcription of proteins from the entire genome.

          Operating upon the principles of retentate chromatography, SELDI MS involves the adsorption of proteins, based upon their physico-chemical properties at a given pH and salt concentration, followed by selectively desorbing proteins from the surface by  
15       varying pH, salt, or organic solvent concentration. After selective desorption, the proteins retained on the SELDI surface, the "chip", can be analyzed using the CIPHERGEN protein detection system, or an equivalent thereof. Retentate chromatography is limited, however, by the fact that if unfractionated body fluids, e.g. blood, blood products, urine, saliva, and the like, along with tissue samples, are applied  
20       to the adsorbent surfaces, the biopolymers present in the greatest abundance will compete for all the available binding sites and thereby prevent or preclude less abundant biopolymers from interacting with them, thereby reducing or eliminating the diversity of biopolymers which are readily ascertainable.

          If a process could be devised for maximizing the diversity of biopolymers  
25       discernable from a sample, the ability of researchers to accurately determine the relevance of such biopolymers with relation to one or more disease states would be immeasurably enhanced.



### SUMMARY OF THE INVENTION

The instant invention is characterized by the use of a combination of preparatory steps in conjunction with SELDI mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

Although all manner of biomarkers related to all disease conditions are deemed to be within the purview of the instant invention and methodology, particular significance was given to those markers and diseases associated with the complement system and Syndrome X and diseases related thereto.

The complement system is an important part of non-clonal or innate immunity that collaborates with acquired immunity to destroy invading pathogens and to facilitate the clearance of immune complexes from the system. This system is the major effector of the humoral branch of the immune system, consisting of nearly 30 serum and membrane proteins. The proteins and glycoproteins composing the complement system are synthesized largely by liver hepatocytes. Activation of the complement system involves a sequential enzyme cascade in which the proenzyme product of one step becomes the enzyme catalyst of the next step. Complement activation can occur via two pathways: the classical and the alternative. The classical pathway is commonly initiated by the formation of soluble antigen-antibody complexes or by the binding of antibody to antigen on a suitable target, such as a bacterial cell. The alternative pathway is generally initiated by various cell-surface constituents that are foreign to the host. Each complement component is designated by numerals (C1-C9), by letter symbols, or by trivial names. After a component is activated, the peptide fragments are denoted by small letters. The complement fragments interact with one another to form functional complexes. Ultimately, foreign cells are destroyed through the process of a membrane-attack complex mediated lysis.

The C4 component of the complement system is involved in the classical

activation pathway. It is a glycoprotein containing three polypeptide chains ( $\alpha$ ,  $\beta$ , and  $\gamma$ ). C4 is a substrate of component C1s and is activated when C1s hydrolyzes a small fragment (C4a) from the amino terminus of the  $\alpha$  chain, exposing a binding site on the larger fragment (C4b).

5           The native C3 component consists of two polypeptide chains,  $\alpha$  and  $\beta$ . As a serum protein, C3 is involved in the alternative pathway. Serum C3, which contains an unstable thioester bond, is subject to slow spontaneous hydrolysis into C3a and C3b. The C3f component is involved in the regulation required of the complement system which confines the reaction to designated targets. During the regulation process, C3b is  
10           cleaved into two parts: C3bi and C3f. C3bi is a membrane-bound intermediate wherein C3f is a free diffusible (soluble) component.

          Complement components have been implicated in the pathogenesis of several disease conditions. C3 deficiencies have the most severe clinical manifestations, such as recurrent bacterial infections and immune-complex diseases, reflecting the central  
15           role of C3. The rapid profusion of C3f moieties and resultant "accidental" lysis of normal cells mediated thereby gives rise to a host of auto-immune reactions. The ability to understand and control these mechanisms, along with their attendant consequences, will enable practitioners to develop both diagnostic and therapeutic avenues by which to thwart these maladies.

20           In the course of defining a plurality of disease specific marker sequences, special significance was given to markers which were evidentiary of a particular disease state or with conditions associated with Syndrome-X. Syndrome-X is a multifaceted syndrome, which occurs frequently in the general population. A large segment of the adult population of industrialized countries develops this metabolic syndrome,  
25           produced by genetic, hormonal and lifestyle factors such as obesity, physical inactivity and certain nutrient excesses. This disease is characterized by the clustering of insulin resistance and hyperinsulinemia, and is often associated with dyslipidemia (atherogenic plasma lipid profile), essential hypertension, abdominal (visceral) obesity, glucose intolerance or noninsulin-dependent diabetes mellitus and an increased risk of  
30           cardiovascular events. Abnormalities of blood coagulation (higher plasminogen activator inhibitor type I and fibrinogen levels), hyperuricemia and microalbuminuria

have also been found in metabolic syndrome-X.

The instant inventors view the Syndrome X continuum in its cardiovascular light, while acknowledging its important metabolic component. The first stage of Syndrome X consists of insulin resistance, abnormal blood lipids (cholesterol and triglycerides), obesity, and high blood pressure (hypertension). Any one of these four first stage conditions signals the start of Syndrome X.

Each first stage Syndrome X condition risks leading to another. For example, increased insulin production is associated with high blood fat levels, high blood pressure, and obesity. Furthermore, the effects of the first stage conditions are additive; an increase in the number of conditions causes an increase in the risk of developing more serious diseases on the Syndrome X continuum.

A patient who begins the Syndrome X continuum risks spiraling into a maze of increasingly deadly diseases. The next stages of the Syndrome X continuum lead to overt diabetes, kidney failure, and heart failure, with the possibility of stroke and heart attack at any time. Syndrome X is a dangerous continuum, and preventative medicine is the best defense. Diseases are currently most easily diagnosed in their later stages, but controlling them at a late stage is extremely difficult. Disease prevention is much more effective at an earlier stage.

Subsequent to the isolation of particular disease state marker sequences as taught by the instant invention, the promulgation of various forms of risk-assessment tests are contemplated which will allow physicians to identify asymptomatic patients before they suffer an irreversible event such as diabetes, kidney failure, and heart failure, and enable effective disease management and preventative medicine. Additionally, the specific diagnostic tests which evolve from this methodology provide a tool for rapidly and accurately diagnosing acute Syndrome X events such as heart attack and stroke, and facilitate treatment.

Accordingly, it is an objective of the instant invention to define a disease specific marker sequence which is useful in evidencing and categorizing at least one particular disease state.

It is another objective of the instant invention to evaluate samples containing a plurality of biopolymers for the presence of disease specific marker sequences which

evidence a link to at least one specific disease state.

It is a further objective of the instant invention to elucidate essentially all biopolymeric moieties contained therein, whereby particularly significant moieties may be identified.

5 It is a further objective of the instant invention provide at least one purified antibody which is specific to said disease specific marker sequence.

It is yet another objective of the instant invention to teach a monoclonal antibody which is specific to said disease specific marker sequence.

10 It is a still further objective of the invention to teach polyclonal antibodies raised against said disease specific marker.

It is yet an additional objective of the instant invention to teach a diagnostic kit for determining the presence of said disease specific marker.

15 It is a still further objective of the instant invention to teach methods for characterizing disease state based upon the identification of said disease specific marker.

20 Other objectives and advantages of this invention will become apparent from the following description taken in conjunction with the accompanying drawings wherein are set forth, by way of illustration and example, certain embodiments of this invention. The drawings constitute a part of this specification and include exemplary embodiments of the present invention and illustrate various objects and features thereof.

#### BRIEF DESCRIPTION OF THE FIGURES

25 Figure 1 is a representation of derived data which characterizes a disease specific marker having a particular sequence useful in evidencing and categorizing at least one particular state;

Figure 2 is the characteristic profile derived via SELDI/TOF MS of the disease specific marker of Figure 1.

DETAILED DESCRIPTION OF THE INVENTION

Serum samples from individuals were analyzed using Surface Enhanced Laser Desorption Ionization (SELDI) using the Ciphergen PROTEINCHIP system. The chip surfaces included, but were not limited to IMAC-3-Ni, SAX2 surface chemistries, gold chips, and the like.

Preparatory to the conduction of the SELDI MS procedure, various preparatory steps were carried out in order to maximize the diversity of discernible moities educable from the sample. Utilizing a type of micro-chromatographic column called a C18- ZIPTIP available from the Millipore company, the following preparatory steps were conducted.

1. Dilute sera in sample buffer;
2. Aspirate and dispense ZIP TIP in 50% Acetonitrile;
3. Aspirate and dispense ZIP TIP in Equilibration; solution;
4. Aspirate and Dispense in serum sample;
5. Aspirate and Dispense ZIP TIP in Wash solution;
6. Aspirate and Dispense ZIP TIP in Elution Solution.

Illustrative of the various buffering compositions useful in the present invention are:

Sample Buffers (various low pH's): Hydrochloric acid (HCl), Formic acid, Trifluoroacetic acid (TFA),

Equilibration Buffers (various low pH's): HCl, Formic acid, TFA;

Wash Buffers (various low pH's): HCl, Formic acid, TFA;

Elution Solutions (various low pH's and % Solvents): HCl, Formic acid, TFA;

Solvents: Ethanol, Methanol, Acetonitrile.

Spotting was then performed, for example upon a Gold Chip in the following manner:

1. spot 2 ul of sample onto each spot
2. let sample partially dry
3. spot 1 ul of matrix, and let air dry.

**HiQ Anion Exchange Mini Column Protocol**

1. Dilute sera in sample/running buffer;
2. Add HiQ resin to column and remove any air bubbles;

3. Add Uf water to aid in column packing;
4. Add sample/running buffer to equilibrate column;
5. Add diluted sera;
6. Collect all the flow through fraction in Eppendorf tubes until level is at resin;

- 
- 5      7. Add sample/running buffer to wash column;
  8. Add elution buffer and collect elution in Eppendorf tubes.

Illustrative of the various buffering compositions useful in this technique are:

- Sample/Running buffers: including but not limited to Bicine buffers of various molarities, pH's, NaCl content, Bis-Tris buffers of various molarities, pH's, NaCl content, Diethanolamine of various molarities, pH's, NaCl content, Diethylamine of various molarities, pH's, NaCl content, Imidazole of various molarities, pH's, NaCl content, Tricine of various molarities, pH's, NaCl content, Triethanolamine of various molarities, pH's, NaCl content, Tris of various molarities, pH's, NaCl content.

- Elution Buffer: Acetic acid of various molarities, pH's, NaCl content, Citric acid of various molarities, pH's, NaCl content, HEPES of various molarities, pH's, NaCl content, MES of various molarities, pH's, NaCl content, MOPS of various molarities, pH's, NaCl content, PIPES of various molarities, pH's, NaCl content, Lactic acid of various molarities, pH's, NaCl content, Phosphate of various molarities, pH's, NaCl content, Tricine of various molarities, pH's, NaCl content.

#### 20      **Chelating Sepharose Mini Column**

1. Dilute Sera in Sample/Running buffer;
2. Add Chelating Sepharose slurry to column and allow column to pack;
3. Add UF water to the column to aid in packing;
4. Add Charging Buffer once water is at the level of the resin surface;
- 25      5. Add UF water to wash through non bound metal ions once charge buffer washes through;
6. Add running buffer to equilibrate column for sample loading;
7. Add diluted serum sample;
8. Add running buffer to wash unbound protein;
- 30      9. Add elution buffer and collect elution fractions for analysis;
10. Acidify each elution fraction.

Illustrative of the various buffering compositions useful in this technique are:  
Sample/Running buffers including but not limited to Sodium Phosphate buffers at various molarities and pH's;

5 Charging buffers including but not limited to Nickel Chloride, Nickel Sulphate, Copper II Chloride, Zinc Chloride or any suitable metal ion solution;

Elution Buffers including but not limited to Sodium phosphate buffers at various molarities and pH's containing various molarities of EDTA and/or Imidazole.

#### HiS Cation Exchange Mini Column Protocol

1. Dilute sera in sample/running buffer;
- 10 2. Add HiS resin to column and remove any air bubbles;
3. Add Uf water to aid in column packing;
4. Add sample/running buffer to equilibrate column for sample loading;
5. Add diluted sera to column;
6. Collect all flow through fractions in Eppendorf tubes until level is at resin.
- 15 7. Add sample/running buffer to wash column.
8. Add elution buffer and collect elution in Eppendorf tubes.

Illustrative of the various buffering compositions useful in this technique are:

Sample/Running buffers: including but not limited to Bicine buffers of various molarities, pH's, NaCl content, Bis-Tris buffers of various molarities, pH's, NaCl content, Diethanolamine of various molarities, pH's, NaCl content, Diethylamine of various molarities, pH's, NaCl content, Imidazole of various molarities, pH's, NaCl content, Tricine of various molarities, pH's, NaCl content, Triethanolamine of various molarities, pH's, NaCl content, Tris of various molarities, pH's, NaCl content.

25 Elution Buffer: Acetic acid of various molarities, pH's, NaCl content, Citric acid of various molarities, pH's, NaCl content, HEPES of various molarities, pH's, NaCl content, MES of various molarities, pH's, NaCl content, MOPS of various molarities, pH's, NaCl content, PIPES of various molarities, pH's, NaCl content, Lactic acid of various molarities, pH's, NaCl content, Phosphate of various molarities, pH's, NaCl content, Tricine of various molarities, pH's, NaCl content.

The procedure for profiling serum samples is described below:

Following the preparatory steps illustrated above, various methods for use of the PROTEINCHIP arrays, available for purchase from CIPHERGEN Biosystems (Palo Alto, CA), may be practiced. Illustrative of one such method is as follows.

---

5           The first step involved treatment of each spot with 20 ml of a solution of 0.5 M EDTA for 5 minutes at room temperature in order to remove any contaminating divalent metal ions from the surface. This was followed by rinsing under a stream of ultra-filtered, deionized water to remove the EDTA. The rinsed surfaces were treated with 20 ml of 100 mM Nickel sulfate solution for 5 minutes at room temperature after  
10       which the surface was rinsed under a stream of ultra-filtered, deionized water and allowed to air dry.

          Serum samples (2 ml) were applied to each spot (now "charged" with the metal-Nickel) and the PROTEINCHIP was returned to the plastic container in which it was supplied. A piece of moist KIMWIPE was placed at the bottom of the container to  
15       generate a humid atmosphere. The cap on the plastic tube was replaced and the chip allowed to incubate at room temperature for one hour. At the end of the incubation period, the chip was removed from the humid container and washed under a stream of ultra-filtered, deionized water and allowed to air dry. The chip surfaces (spots) were now treated with an energy-absorbing molecule that helps in the ionization of the  
20       proteins adhering to the spots for analysis by Mass Spectrometry. The energy-absorbing molecule in this case was sinapinic acid and a saturated solution prepared in 50% acetonitrile and 0.05% TFA was applied (1 ml) to each spot. The solution was allowed to air dry and the chip analyzed immediately using MS (SELDI).

          Serum samples from patients suffering from a variety of disease states were  
25       analyzed using one or more protein chip surfaces, e.g. a gold chip or an IMAC nickel chip surface as described above and the profiles were analyzed to discern notable sequences which were deemed in some way evidentiary of at least one disease state.

          In order to purify the disease specific marker and further characterize the sequence thereof, additional processing was performed.

30       For example, Serum (20 ml) was (diluted 5-fold with phosphate buffered saline) concentrated by centrifugation through a YM3 MICROCON spin filter (Amicon) for 20



min at 10,000 RPM at 4°C in a Beckman MICROCENTRIFuge R model bench top centrifuge. The filtrate was discarded and the retained solution, which contained the two peptides of interest, was analyzed further by tandem mass spectrometry to deduce their amino acid sequences. Tandem mass spectrometry was performed at the  
5 University of Manitoba's (Winnipeg, Manitoba, Canada) mass spectrometry laboratory using the procedures that are well known to practitioners of the art.

As a result of these procedures, the disease specific marker having a sequence identified as SEQ ID NO: 1 was found. This marker is characterized as a C3f fragment from the complement system having a molecular weight of about 2021 daltons. The  
10 characteristic profile of the marker is set forth in Figure 2. As easily deduced from the data set forth in Figure 1, this marker is indicative of an individual suffering from myocardial infarction, congestive heart failure, or Type II diabetes.

In accordance with various stated objectives of the invention, the skilled artisan, in possession of the specific disease specific marker as instantly disclosed, would  
15 readily carry out known techniques in order to raise purified biochemical materials, e.g. monoclonal and/or polyclonal antibodies, which are useful in the production of methods and devices useful as point-of-care rapid assay diagnostic or risk assessment devices as are known in the art.

The specific disease markers which are analyzed according to the method of the  
20 invention are released into the circulation and may be present in the blood or in any blood product, for example plasma, serum, cytolyzed blood, e.g. by treatment with hypotonic buffer or detergents and dilutions and preparations thereof, and other body fluids, e.g. CSF, saliva, urine, lymph, and the like. The presence of each marker is determined using antibodies specific for each of the markers and detecting specific  
25 binding of each antibody to its respective marker. Any suitable direct or indirect assay method may be used to determine the level of each of the specific markers measured according to the invention. The assays may be competitive assays, sandwich assays, and the label may be selected from the group of well-known labels such as radioimmunoassay, fluorescent or chemiluminescence immunoassay, or immunoPCR  
30 technology. Extensive discussion of the known immunoassay techniques is not required

here since these are known to those of skilled in the art. See Takahashi et al. (Clin Chem 1999;45(8):1307) for S100B assay.

A monoclonal antibody specific against the disease marker sequence isolated by the present invention may be produced, for example, by the polyethylene glycol (PEG)

5 mediated cell fusion method, in a manner well-known in the art.

Traditionally, monoclonal antibodies have been made according to fundamental principles laid down by Kohler and Milstein. Mice are immunized with antigens, with or without, adjuvants. The splenocytes are harvested from the spleen for fusion with immortalized hybridoma partners. These are seeded into microtitre plates where they  
10 can secrete antibodies into the supernatant that is used for cell culture. To select from the hybridomas that have been plated for the ones that produce antibodies of interest the hybridoma supernatants are usually tested for antibody binding to antigens in an ELISA (enzyme linked immunosorbent assay) assay. The idea is that the wells that contain the hybridoma of interest will contain antibodies that will bind most avidly to the test  
15 antigen, usually the immunizing antigen. These wells are then subcloned in limiting dilution fashion to produce monoclonal hybridomas. The selection for the clones of interest is repeated using an ELISA assay to test for antibody binding. Therefore, the principle that has been propagated is that in the production of monoclonal antibodies the hybridomas that produce the most avidly binding antibodies are the ones that are  
20 selected from among all the hybridomas that were initially produced. That is to say, the preferred antibody is the one with highest affinity for the antigen of interest.

There have been many modifications of this procedure such as using whole cells for immunization. In this method, instead of using purified antigens, entire cells are used for immunization. Another modification is the use of cellular ELISA for  
25 screening. In this method instead of using purified antigens as the target in the ELISA, fixed cells are used. In addition to ELISA tests, complement mediated cytotoxicity assays have also been used in the screening process. However, antibody-binding assays were used in conjunction with cytotoxicity tests. Thus, despite many modifications, the process of producing monoclonal antibodies relies on antibody binding to the test  
30 antigen as an endpoint.

The purified monoclonal antibody is utilized for immunochemical studies.

Polyclonal antibody production and purification utilizing one or more animal hosts in a manner well-known in the art can be performed by a skilled artisan.

Another objective of the present invention is to provide reagents for use in diagnostic assays for the detection of the particularly isolated disease specific marker sequences of the present invention.

In one mode of this embodiment, the marker sequences of the present invention may be used as antigens in immunoassays for the detection of those individuals suffering from the disease known to be evidenced by said marker sequence. Such assays may include but are not limited to: radioimmunoassay, enzyme-linked immunosorbent assay (ELISA), "sandwich" assays, precipitin reactions, gel diffusion immunodiffusion assay, agglutination assay, fluorescent immunoassays, protein A or G immunoassays and immunoelectrophoresis assays.

According to the present invention, monoclonal or polyclonal antibodies produced against the disease specific marker sequence of the instant invention are useful in an immunoassay on samples of blood or blood products such as serum, plasma or the like, spinal fluid or other body fluid, e.g. saliva, urine, lymph, and the like, to diagnose patients with the characteristic disease state linked to said marker sequence. The antibodies can be used in any type of immunoassay. This includes both the two-site sandwich assay and the single site immunoassay of the non-competitive type, as well as in traditional competitive binding assays.

Particularly preferred, for ease and simplicity of detection, and its quantitative nature, is the sandwich or double antibody assay of which a number of variations exist, all of which are contemplated by the present invention. For example, in a typical sandwich assay, unlabeled antibody is immobilized on a solid phase, e.g. microtiter plate, and the sample to be tested is added. After a certain period of incubation to allow formation of an antibody-antigen complex, a second antibody, labeled with a reporter molecule capable of inducing a detectable signal, is added and incubation is continued to allow sufficient time for binding with the antigen at a different site, resulting with a formation of a complex of antibody-antigen-labeled antibody. The presence of the antigen is determined by observation of a signal which may be quantitated by comparison with control samples containing known amounts of antigen.

All patents and publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

It is to be understood that while a certain form of the invention is illustrated, it is not to be limited to the specific form or arrangement herein described and shown. It will be apparent to those skilled in the art that various changes may be made without departing from the scope of the invention and the invention is not to be considered limited to what is shown and described in the specification and drawings/figures.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objectives and obtain the ends and advantages mentioned, as well as those inherent therein. The oligonucleotides, peptides, polypeptides, biologically related compounds, methods, procedures and techniques described herein are presently representative of the preferred embodiments, are intended to be exemplary and are not intended as limitations on the scope. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention and are defined by the scope of the appended claims. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the following claims.

CLAIMS

What is claimed is:

Claim 1. A biopolymer marker having a sequence identified as SEQ ID NO: 1 useful in indicating at least one particular disease state.

Claim 2. The biopolymer marker of claim 1 wherein said disease state is from the group of myocardial infarction, congestive heart failure, or Type II diabetes.

Claim 3. A method for evidencing and categorizing at least one disease state comprising:

obtaining a sample from a patient;

conducting mass spectrophotometric analysis on said sample;

evidencing and categorizing at least one biopolymer marker sequence or analyte thereof isolated from said sample; and,

comparing said at least one isolated biopolymer marker sequence or analyte thereof to the biopolymer marker sequence as set forth in claim 1;

wherein correlation of said isolated biopolymer marker and said biopolymer marker sequence as set forth in claim 1 evidences and categorizes said at least one disease state.

Claim 4. The method of claim 3, wherein said step of evidencing and categorizing is particularly directed to biopolymer markers or analytes thereof linked to at least one risk of disease development of said patient.

Claim 5. The method of claim 3, wherein said step of evidencing and categorizing is particularly directed to biopolymer markers or analytes thereof related to the existence of a particular disease state.

Claim 6. The method of claim 3, wherein the sample is an unfractionated body fluid or a tissue sample.

Claim 7. The method of claim 3, wherein said sample is at least one of the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

---

Claim 8. The method of claim 3, wherein said mass spectrophotometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

Claim 9. The method of claim 3, wherein said patient is a human.

Claim 10. A diagnostic assay kit for determining the presence of the biopolymer marker or analyte thereof of claim 1 comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least said biopolymer marker or analyte thereof, and means for determining binding between said biochemical material and said biomolecule.

Claim 11. The diagnostic assay kit of claim 10, wherein said biochemical material or biomolecule is immobilized on a solid support.

Claim 12. The diagnostic assay kit of claim 10 including:  
at least one labeled biochemical material.

Claim 13. The diagnostic assay kit of claim 10, wherein said biochemical material is an antibody.

Claim 14. The diagnostic assay kit of claim 12, wherein said labeled biochemical material is an antibody.

Claim 15. The diagnostic assay kit of claim 10, wherein the sample is an unfractionated body fluid or a tissue sample.

Claim 16. The diagnostic assay kit of claim 10, wherein said sample is at least one of the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 17. The diagnostic assay kit of claim 10, wherein said marker includes the sequence identified as SEQ ID NO: 1 and said biochemical material is at least one monoclonal antibody specific therefore.

Claim 18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker including the sequence identified as SEQ ID NO: 1 or an analyte thereof related to said disease state; and means for determining binding between said biochemical material and said biomolecule;

whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

Claim 19. The kit of claim 18, wherein said biochemical material or biomolecule is immobilized on a solid support.

Claim 20. The kit of claim 18 including:  
at least one labeled biochemical material.

Claim 21. The kit of claim 18, wherein said biochemical material is an antibody.

Claim 22. The kit of claim 20, wherein said labeled biochemical material is an antibody.

Claim 23. The kit of claim 18, wherein the sample is an unfractionated body fluid or a tissue sample.

---

Claim 24. The kit of claim 18, wherein said sample is at least one of the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.

Claim 25. The kit of claim 18, wherein said marker includes the sequence identified as SEQ ID NO: 1 or at least one analyte thereof and said biochemical material is at least one monoclonal antibody specific therefore.

Claim 26. The kit of claim 18, wherein said diagnosing, determining risk assessment, and identifying therapeutic avenues is carried out on a single sample.

Claim 27. The kit of claim 18, wherein said diagnosing, determining risk assessment, and identifying therapeutic avenues is carried out on multiple samples such that at least one analysis is carried out on a first sample and at least another analysis is carried out on a second sample.

Claim 28. The kit of claim 27, wherein said first and second samples are obtained at different time periods.

Claim 29. Polyclonal antibodies produced against the marker having a sequence identified as SEQ ID NO: 1 in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including the marker sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

Claim 31. The antibody of claim 30 that is a monoclonal antibody.



Claim 32. The antibody of claim 30 that is a polyclonal antibody.

Claim 33. A process for identifying therapeutic avenues related to a disease state comprising:

conducting an analysis as provided by the kit of claim 18; and

interacting with a biopolymer including the sequence identified as SEQ ID NO:

1 or at least one analyte thereof;

whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof.


Claim 35. A process for regulating a disease state by controlling the presence or absence of a biopolymer including the sequence identified as SEQ ID NO: 1 or at least one analyte thereof.

Figure 1  
Bleopolymer Indicative of Disease State - MW 2021

Code #	Gender	Age	Patient History	Disease	MW	Protein Name	Sequence
SJ CON 01	M	62		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 06	F	77		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 08	F	77		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 09	M	80		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-002	M	81		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-009	M	78		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-024	M	63		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-039	M	62		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
184-988	M	73		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
734-989	M	65		Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 07	M	65		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 10	F	60		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 14	F	65		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 17	M	68		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 19	M	62		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
SJ CON 21	M	65		MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
HNS-SJ22				MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
HNS-SJ28				MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
HNS-SJ33				MI	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23804-KXB	M	61	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23707-KL	F	66	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
22703-MMS	F	67	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
20206-MM	F	75	STAGE 4	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
21813-GM	F	77	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
21813-GR	F	66	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23008-GFB	M	67	STAGE3 - DEAD	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23402-HM	M	67	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
20208-HIF	M	79	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
22803-HB	M	60	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23616-JGK	M	43	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
20803-EW	M	45	Acute MI - STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23421-FB	M	59	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
22813-CL	F	68	STAGE 4	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23130-ER	M	51	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23105-FC	M	64	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23116-FC	M	69	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
20414-EYG	F	78	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23130-ER	M	61	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
23134-FC	M	82	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
20102-EAB	M	70	STAGE 3	CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-002				CHF	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-009				Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-024				Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
TWH-039				Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
184-988				Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ
734-989				Type II Diabetes	2021	Complement C3f	(*)SSKITHRIHWESASLLRQ

2/2

SPECTRA SHOWING DISEASE INDICATIVE MARKER  
FIGURE 2



## SEQUENCE LISTING

<110> Jackowski, George

<120> BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A  
MOLECULAR WEIGHT OF 2021 DALTONS

<130> 2132.048

<140> 09/846,344

<141> 2001-04-30

<160> 1

<170> PatentIn version 3.1

<210> 1

<211> 17

<212> PRT

<213> Homo sapiens

<400> 1

Ser Ser Lys Ile Thr His Arg Ile His Trp Glu Ser Ala Ser Leu Leu

1

5

10

15

Arg

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 November 2002 (07.11.2002)

PCT

(10) International Publication Number  
WO 02/088711 A3

- (51) International Patent Classification<sup>7</sup>: G01N 33/68, C07K 7/08, 16/36
- (21) International Application Number: PCT/CA02/00627
- (22) International Filing Date: 29 April 2002 (29.04.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/846,344 30 April 2001 (30.04.2001) US
- (71) Applicant: SYN.X PHARMA, INC. [CA/CA]; 6354 Viscount Road, Mississauga, Ontario L4V 1H3 (CA).
- (72) Inventors: JACKOWSKI, George; 11725 Keele Street R1, Kettleby, Ontario L0G 1J0 (CA). THATCHER, Brad; 12 Beaverdale Road, Toronto, Ontario M8Y 3Y4 (CA). VREES, Tammy; 215 Bronte Road, Oakville, Ontario L6L 3C5 (CA). YANTHA, Jason; 44 St. Joseph Street, Apartment 2102, Toronto, Ontario M4Y 2W4 (CA). MARSHALL, John; 95 Parkside Drive, Toronto, Ontario M6R 2V3 (CA).
- (74) Agent: SINGLEHURST, John, C.; Finlayson & Singlehurst, 70 Gloucester Street, Ottawa, Ontario K2P 0A2 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:  
— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations

[Continued on next page]

(54) Title: BIOPOLYMER MARKER INDICATIVE OF DISEASE STATE HAVING A MOLECULAR WEIGHT OF 2021 DALTONS

Biopolymer Indicative of Disease State - MW 2021

Code #	Genetic Age	Age	Patient History	Disease	MW	Protein Name	Sequence
BU CON 01	M	82		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
BU CON 06	F	77		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
BU CON 08	F	77		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
BU CON 09	F	77		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 002	M	81		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 008	M	78		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 009	M	83		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 023	M	82		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 026	M	75		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 028	M	85		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 029	M	82		Type II Diabetes	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 030	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 031	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 032	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 033	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 034	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 035	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 036	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 037	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 038	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 039	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 040	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 041	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 042	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 043	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 044	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 045	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 046	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 047	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 048	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 049	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 050	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 051	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 052	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 053	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 054	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 055	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 056	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 057	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 058	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 059	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 060	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 061	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 062	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 063	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 064	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 065	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 066	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 067	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 068	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 069	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 070	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 071	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 072	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 073	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 074	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 075	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 076	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 077	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 078	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 079	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 080	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 081	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 082	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 083	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 084	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 085	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 086	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 087	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 088	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 089	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 090	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 091	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 092	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 093	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 094	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 095	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 096	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 097	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 098	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 099	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 100	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 101	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 102	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 103	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 104	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 105	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 106	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 107	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 108	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 109	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 110	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 111	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 112	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 113	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 114	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 115	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 116	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 117	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 118	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 119	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 120	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 121	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 122	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 123	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 124	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 125	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 126	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 127	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 128	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 129	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 130	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 131	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 132	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 133	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 134	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 135	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 136	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 137	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 138	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 139	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 140	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 141	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 142	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 143	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 144	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 145	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 146	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 147	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 148	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 149	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 150	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 151	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 152	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 153	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 154	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 155	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 156	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 157	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 158	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 159	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 160	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 161	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 162	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 163	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 164	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 165	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 166	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 167	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 168	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 169	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 170	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 171	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 172	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 173	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 174	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 175	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 176	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 177	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 178	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 179	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 180	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 181	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 182	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 183	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 184	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 185	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 186	M	82		MI	2021	Complement C2F	(YSGNTHRWVWESASLRLN)
YWH 187	M	82		MI	2021	Complement C2F	



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**(88) Date of publication of the international search report:**

16 January 2003

## INTERNATIONAL SEARCH REPORT

 International Application No  
 PCT/CA 02/00627

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 G01N33/68 C07K7/08 C07K16/36		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, MEDLINE, BIOSIS, WPI Data, PAJ, SEQUENCE SEARCH, CHEM ABS Data		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HARRISON, RICHARD A. ET AL: "Structure of C3f, a small peptide specifically released during inactivation of the third component of complement" COMPLEMENT, vol. 5, no. 1, 1988, pages 27-32, XP008007942 figure 1	1,2
X	WO 87 06344 A (NILSSON ULF R; NILSSON S I BO; SVENSSON KARL ERIK) 22 October 1987 (1987-10-22) page 6, line 13 - line 21 page 12, paragraph 4 - page 17, paragraph 3	10-32
X	WO 91 13352 A (BRIGHAM & WOMENS HOSPITAL) 5 September 1991 (1991-09-05) page 34, line 4 - line 5	29-32
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search  18 September 2002		Date of mailing of the international search report  26/11/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Gunster, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/00627

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TANG S ET AL: "Contribution of renal secreted complement C3 to the circulating pool in humans." JOURNAL OF IMMUNOLOGY , vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 4336-4341, XP002213827 ISSN: 0022-1767 page 4337, column 2, paragraph 2 - paragraph 4	29-32
X	WO 98 32390 A (UAB RESEARCH FOUNDATION) 30 July 1998 (1998-07-30) example 5	29, 30, 32
X	KOCH C ET AL: "A novel polymorphism of human complement component C3 detected by means of a monoclonal antibody." IMMUNOGENETICS. UNITED STATES 1986, vol. 23, no. 5, 1986, pages 322-325, XP008008260 ISSN: 0093-7711 the whole document	30, 31
Y	WO 01 05422 A (KOLBE H; MALCUS C; PERRON H; SANTORO L) 25 January 2001 (2001-01-25) claims 40, 44; example 10	3-9, 33-35
Y	MUSCARI ANTONIO ET AL: "Association of serum C3 levels with the risk of myocardial infarction." AMERICAN JOURNAL OF MEDICINE, vol. 98, no. 4, 1995, pages 357-364, XP008008225 ISSN: 0002-9343 abstract	3-9, 33-35
A	AGARWAL R ET AL: "Immunologic parameters in infective endocarditis: a prospective study." INDIAN HEART JOURNAL. INDIA 1991 MAY-JUN, vol. 43, no. 3, May 1991 (1991-05), pages 179-183, XP008008224 ISSN: 0019-4832 abstract	3-9
A	KRISTENSEN B O ET AL: "ASSOCIATION BETWEEN CORONARY HEART DISEASE AND THE COMPLEMENT C-3F GENE IN ESSENTIAL HYPERTENSION" CIRCULATION, vol. 58, no. 4, 1978, pages 622-625, XP008008221 ISSN: 0009-7322 abstract	3-9

-/-



## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 02/00627

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WEYER C ET AL: "Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration." DIABETES CARE, vol. 23, no. 6, 2000, pages 779-785, XP002213828 ISSN: 0149-5992 abstract -----	3-9
A	WO 00 49410 A (EMMERT BUCK MICHAEL; SIMONE NICOLE (US); US HEALTH (US); LIOTTA LA) 24 August 2000 (2000-08-24) claims 10,11; example 5 -----	3,8
A	US 5 538 897 A (ENG JAMES K ET AL) 23 July 1996 (1996-07-23) the whole document -----	3

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 02/00627

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 3-9 'partially!', 35 'partially!'  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210**

Continuation of Box I.1

Although claims 3-9 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the method.

Although claim 35 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of biopolymer marker including SEQ ID NO: 1.

---

Continuation of Box I.1

Claims Nos.: 3-9'partially!', 35'partially!'

Rule 39.1(iv) PCT - Diagnostic method practised on the human or animal body

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 02/00627

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8706344	A	22-10-1987	SE 452065 B AU 7286887 A EP 0263161 A1 JP 63503089 T SE 8601644 A WO 8706344 A1	09-11-1987 09-11-1987 13-04-1988 10-11-1988 12-10-1987 22-10-1987
WO 9113352	A	05-09-1991	AU 649435 B2 AU 7461991 A CA 2077438 A1 EP 0517802 A1 WO 9113352 A1 US 5474927 A US 5665556 A	26-05-1994 18-09-1991 03-09-1991 16-12-1992 05-09-1991 12-12-1995 09-09-1997
WO 9832390	A	30-07-1998	US 5778895 A AU 748600 B2 AU 6250398 A EP 0973456 A1 WO 9832390 A1	14-07-1998 06-06-2002 18-08-1998 26-01-2000 30-07-1998
WO 0105422	A	25-01-2001	FR 2797402 A1 AU 6576800 A EP 1203239 A2 WO 0105422 A2	16-02-2001 05-02-2001 08-05-2002 25-01-2001
WO 0049410	A	24-08-2000	AU 3367100 A EP 1153300 A2 WO 0049410 A2	04-09-2000 14-11-2001 24-08-2000
US 5538897	A	23-07-1996	CA 2185574 A1 EP 1239288 A1 EP 0750747 A1 JP 3195358 B2 JP 9510780 T WO 9525281 A1 US 6017693 A	21-09-1995 11-09-2002 02-01-1997 06-08-2001 28-10-1997 21-09-1995 25-01-2000